Skip to Main Content

Hepatoblastoma Treatment

Hepatoblastoma is a type of liver cancer that is usually found in babies and children up to age 3. But it can affect children of all ages. Hepatoblastoma is the most common childhood liver cancer, but it is rare. It is diagnosed in fewer than 1 in 1 million children. 

The survival rate for hepatoblastoma is more than 80% (8 in 10) if the tumor is only in the liver and can be completely removed with surgery after chemotherapy.

Survival rates for children whose tumors involve the entire liver or have spread outside the liver range from 20% (2 in 10) to 70% (7 in 10) at 3–5 years after diagnosis.

Find out more about hepatoblastoma on the Together by St. Jude™ online resource.

Treatment of hepatoblastoma

Surgery is used to remove all of the hepatoblastoma tumor. It is the most important part of treatment. If the entire liver is affected, your child may need a liver transplant to remove all of the tumor.

Chemotherapy uses powerful medicines to kill cancer cells or stop them from spreading.  Some patients are able to have surgery upfront. But most have chemotherapy before surgery to shrink the tumor and make it easier to remove. Some patients will get chemotherapy after surgery to keep the cancer from coming back.

Hepatoblastoma clinical trials

St. Jude Children’s Research Hospital offers clinical trials and cancer research studies for children, teens, and young adults with liver cancer.  Learn more about clinical trials at St. Jude.

Open clinical trials for hepatoblastoma

ONITT: Study of Onivyde with Talazoparib or Temozolomide in Children and Young Adults with Recurrent/Refractory Solid Tumors and Ewing Sarcoma

Study goal:

The main goal of this study is to test new experimental drugs in hopes of finding a treatment that may work against tumors that have come back or that have not responded to standard therapy in children, adolescents and young adults.


12 months to 30 years old

3CAR: B7-H3-specific CAR T-cell Therapy for Children and Young Adults with Solid Tumors

Study goal:

The main purpose of 3CAR is to find out if this type of immunotherapy is safe for pediatric patients with solid tumors. We also want to learn if it is effective in fighting solid tumors.


Up to 21 years old

PEPN2011: Tegavivint Treatment for Solid Tumors, Lymphomas, and Desmoid Tumors

Study goal:

The main purpose of this study is to find out how well the medicine tegavivint works to help children, teens, and young adults with certain recurrent or refractory solid tumors.


12 months to 30 years

Hepatoblastoma care at St. Jude

St. Jude provides the highest quality of care for patients with pediatric liver cancer:

  • St. Jude offers a dedicated team of specialists to meet the needs of children with hepatoblastoma, including:
  • Complete, quality surgery is an important part of treating hepatoblastoma. The expert skills and experience of St. Jude surgeons can help improve patients’ chances for the best outcomes.
  • St. Jude has access to new “experimental” medicines that can be used if the cancer comes back or does not respond to treatment.
  • St. Jude is committed to finding cures and limiting side effects. Children are not just small people. Their bodies and systems are unique, along with the disorders that affect them. For the best care, they need a specialized team. That is what you get at St. Jude.
  • St. Jude practices patient family-centered care. Patient family-centered care is health care that focuses on the family as a child’s primary source of strength, support and well-being. At the heart of patient family-centered care is the belief that the health care team and the family are partners, working together to best meet the needs of the child. Excellence in health care happens when we work together and honor the expertise each of us brings to every health care encounter.

More reasons to choose St. Jude for care include:

  • We are consistently ranked among the best childhood cancer centers in the nation by US News & World Report. 
  • At St. Jude, we have created an environment where children can be children and families can be together. 
  • We lead more clinical trials for childhood cancer than any other hospital in the U.S.  
  • St. Jude is the only National Cancer Institute–designated Comprehensive Cancer Center just for children. A Comprehensive Cancer Center meets rigorous standards for research that develops new and better approaches to prevent, diagnose, and treat cancer. 
  • The nurse-to-patient ratio at St. Jude is unmatched. It is about 1:3 in hematology and oncology and 1:1 in the Intensive Care Unit. 
  • Patients may be able to get expert, compassionate care and treatment closer to their homes through the St. Jude Affiliate Program. 
A statue of children running and holding hands

Seeking treatment at St. Jude

Patients accepted to St. Jude must have a disease we treat and must be referred by a physician or other qualified medical professional. We accept most patients based on their ability to enroll in an open clinical trial.

How to seek treatment

Contact the Physician / Patient Referral Office

Call: 1-888-226-4343 (toll-free) or 901-595-4055 (local)  | Fax: 901-595-4011 | Email: | 24-hour pager: 1-800-349-4334

The solid tumor coordinator is dedicated to helping you seek treatment or refer a patient.

Solid Tumor Coordinator


Learn more